Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Reinforcing Exercise in Substance Abusing Patients
Conditions: Substance Abuse - Contingency Management - Exercise
Location: Hartford, Connecticut
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Eureka, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Eureka, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Kewanee, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Ottawa, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Ottawa, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peoria, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peoria, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peru, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peru, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Princeton, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Princeton, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Spring Valley, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Eureka, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Ottawa, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peoria, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peoria, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peru, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Princeton, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Eureka, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Eureka, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Kewanee, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Ottawa, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Ottawa, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peoria, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peoria, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peru, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peru, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Princeton, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Princeton, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Spring Valley, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Eureka, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Eureka, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottawa, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottawa, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peoria, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peoria, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peru, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peru, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Princeton, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Spring Valley, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Kewanee, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Spring Valley, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Eureka, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peoria, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peoria, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peru, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Princeton, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Spring Valley, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Eureka, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Eureka, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Kewanee, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peoria, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peoria, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peru, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peru, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Princeton, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Princeton, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Spring Valley, Illinois
- E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Conditions: Bladder Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Kewanee, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peru, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peru, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Princeton, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Princeton, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Spring Valley, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Kewanee, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Spring Valley, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Spring Valley, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Eureka, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Eureka, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Kewanee, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Ottawa, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Ottawa, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peoria, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peoria, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peru, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peru, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Princeton, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Princeton, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Spring Valley, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Kewanee, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peoria, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peoria, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peru, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peru, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Princeton, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Princeton, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Spring Valley, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Eureka, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Eureka, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Kewanee, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottawa, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottawa, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peoria, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peoria, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peru, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peru, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Princeton, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Princeton, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Spring Valley, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Kewanee, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Spring Valley, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Kewanee, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Spring Valley, Illinois
- IMC-A12 and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Malignant Fibrous Histiocytoma of Bone - Sarcoma
Location: Peoria, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Eureka, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Eureka, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Kewanee, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Peoria, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Peoria, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Peru, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Peru, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Princeton, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Princeton, Illinois
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Spring Valley, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Eureka, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Eureka, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Kewanee, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Ottawa, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Ottawa, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Peoria, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Peoria, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Peru, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Peru, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Princeton, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Princeton, Illinois
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Spring Valley, Illinois
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Ottawa, Illinois
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Ottawa, Illinois
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Peoria, Illinois
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Peoria, Illinois
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Peoria, Illinois
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Spring Valley, Illinois
- A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Wo
Conditions: Breast Cancer
Location: Peoria, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Eureka, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Eureka, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Kewanee, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Ottawa, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Ottawa, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Peoria, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Peoria, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Peru, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Peru, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Princeton, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Princeton, Illinois
- Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III
Conditions: Lymphoma
Location: Spring Valley, Illinois
- Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Conditions: Head and Neck Cancer
Location: Peoria, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Eureka, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Eureka, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Kewanee, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Ottawa, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Ottawa, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Peoria, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Peoria, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Peru, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Peru, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Princeton, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Princeton, Illinois
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Spring Valley, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Eureka, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Eureka, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Kewanee, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Ottawa, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Ottawa, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Peoria, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Peoria, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Peru, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Peru, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Princeton, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Princeton, Illinois
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Spring Valley, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peru, Illinois
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Princeton, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Eureka, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Eureka, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Kewanee, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Ottawa, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Ottawa, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Peoria, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Peoria, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Peru, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Peru, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Princeton, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Princeton, Illinois
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Spring Valley, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Eureka, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Eureka, Illinois
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Kewanee, Illinois
|